Results 121 to 130 of about 11,409 (260)

Safety and pharmacokinetics of inhaled aloxistatin: A first‐in‐human phase 1 dose escalation trial

British Journal of Clinical Pharmacology, EarlyView.
Aims Aloxistatin (E64d) is a membrane‐permeable cysteine protease inhibitor prodrug that is converted by esterases to the active metabolite E64c (loxistatin). This first‐in‐human study evaluated the safety, tolerability and pharmacokinetics of single ascending doses of inhaled E64d in healthy volunteers.
Sebastian Fähndrich, Franziska Friedrich, Daniel Soriano, Jona Gjeloshi, Björn C. Frye, Xuan Phuoc Nguyen, Lydia Herbstritt, Caroline von Spee‐Mayer, Britta Lang, Fabrice Nollevaux, Andreas Hoheisel, Dorothee Winterberg, Armin Braun, Thomas Epting, Christine Contini, Karl Winkler, Thomas Reinheckel, Franziska C. Trudzinski, Gernot Rohde, Daiana Stolz, Robert Bals, Martin J. Hug, Sebastian Wirtz, Christoph Peters, Carolin Jenkner   +24 more
wiley   +1 more source

Technical Aspects for the Evaluation of Circulating Tumor Cells (CTCs)

, 2017
Liquid biopsy is considered a valid strategy to improve patients’ selection and treatment monitoring in clinical practice. Indeed Circulating Tumor Cells (CTCs) represent an important component of liquid biopsy and their clinical evaluation is becoming ...
Bazan, Viviana, Ciaccio, M., Viviana Bazan, Di Stefano, A. B., Castiglia, M., M. Castiglia, M. Ciaccio, A. B. Di Stefano   +7 more
core   +1 more source

Structural compatibility between β‐lactams and substrate binding pockets of IMP‐1 and NDM‐1 determines the substrate spectrum

Bulletin of the Korean Chemical Society, EarlyView.
Chemical structures of three β‐lactam classes and the substrate‐binding pockets (SBPs) of B1 metallo‐β‐lactamases (MBLs) were compared. Structural compatibility between β‐lactams and MBL SBPs correlates with enzymatic activity, providing insights into the substrate spectrum of MBLs and β‐lactam resistance.
Kiwoong Kwak, Jiwon Yun, Donghyun Lee, Byung‐Jin Lee, Juyeon Lim, Jung Hun Lee, Sang Hee Lee, Soon Young Shin, Lin‐Woo Kang   +8 more
wiley   +1 more source

Small cell size circulating tumor cells predict the prognosis of high-risk non-muscle invasive bladder cancer patients

Scientific Reports
The study aimed to explore the distribution of circulating tumor cells (CTCs), circulating tumor endothelial cells (CTECs), and their subtypes in non-cancer and bladder cancer individuals, focusing on their prognostic value in high-risk non-muscle ...
Yuheng Wen, Zhihao Ming, Yichen Xiong, Hong Li, Shuai Zhu, Jian Cao, Mingji Ye, Tian Gan, Bangwen Yin, Xiangqun She, Yong Zeng, Yu Xie   +11 more
doaj   +1 more source

Comparison of two methods in CTCs counts per 5

, 2013
Comparison of two methods in CTCs counts per ...
Chunping Jia (459179), Weiqi Sheng (137683), Wenjie Sun (164921), Qinghui Jin (459182), Gang Li (34549), Fengxiang Jing (459181), Ting Huang (190932), Jianlong Zhao (459183), Guichao Li (286473), Honglian Zhang (459180), Zhen Zhang (86004)   +10 more
core   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

A Look Inside Community Technology Centers (CTCs): Understanding how CTCs create curriculum in the Chicagoland area [PDF]

, 2015
This study identifies how CTCs select curriculum based on five categories when serving underserved populations. The purpose of study is to understand how CTCs currently serve communities in order to best identify how customized programs can alleviate ...
Mullons, Gloria D
core  

Representative images of CTCs identified.

, 2016
Representative CTC images from cell lines (A) LNCaP, (B) PC3, and (C) VCaP. Slides were stained with CK, AR, CD45, and DAPI. Individual CTCs were identified by Epic Sciences’ algorithm and visually confirmed.
Laura J. Leitz (3350075), Shannon L. Werner (3350087), Shidong Jia (3350105), Eric K. Tucker (3350081), Premal Patel (3350090), Liangxuan Zhang (3350102), Michael Malchiodi (3350093), Yipeng Wang (9800), Stephanie B. Greene (460558), Ryon P. Graf (3350084), Dena Marrinucci (40175), Steven Gendreau (3350078), Angel E. Dago (607604), Ryan Dittamore (3350099), Mark Landers (214385), Jerry Lee (3350096)   +15 more
core   +1 more source

Nanomedicine‐driven innovations in postoperative cancer immunotherapy: Remodeling tumor microenvironment and precision delivery strategies

BMEMat, EarlyView.
Nanomedicine‐Driven Strategies for Suppressing Postoperative Tumor Recurrence. This schematic illustrates three pivotal nanomedical strategies that synergistically counteract recurrence by targeting residual disease and the immunosuppressive tumor microenvironment within the surgical cavity.
Lisong Pang, Zhuomin Wang, Zhenhua Jin, Ahmed H. Ghonaim, Hengcheng Zhang, Xinyu You, Jinzhuo Ning, Jiaqing Cao, Yang Liu   +8 more
wiley   +1 more source

Abstract 1714: Translating CTCs for clinical use: melanoma patient-derived CTCs evolution in xenografts

, 2017
Circulating tumor cells (CTCs) are known to disseminate from primary/metastatic tumors, survive in the circulation, and develop competency to colonize distant organs.
Marc L. Sprouse, Jean P. Thiery, Wei Yin, Dario Marchetti, Monika Vishnoi, Haowen N. Liu, Debasish Boral, Isabella C. Glitza   +7 more
core   +1 more source